Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Actelion, Nippon Shinyaku Join Forces on PAH Compound
RxTrials Institute Drug Pipeline Alert
April 23, 2008 | Vol. 6 No. 17
Actelion, Nippon Shinyaku Join Forces on PAH Compound
Swiss drugmaker Actelion and Japan’s Nippon Shinyaku have signed a license agreement for NS-304, a treatment for pulmonary arterial hypertension (PAH).
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.